Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

@article{Gautret2020HydroxychloroquineAA,
  title={Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial},
  author={Philippe Gautret and Jean-Christophe Lagier and Philippe Parola and Van Thuan Hoang and Line Meddeb and Morgane Mailhe and Barbara Doudier and Johan Courjon and Valérie Giordanengo and Vera Esteves Vieira and Herv{\'e} Tissot Dupont and St{\'e}phane Honor{\'e} and Philippe Colson and Eric Chabri{\`e}re and Bernard La Scola and J M Rolain and Philippe Brouqui and Didier Raoult},
  journal={International Journal of Antimicrobial Agents},
  year={2020},
  volume={56},
  pages={105949 - 105949}
}
Abstract Background Chloroquine and hydroxychloroquine have been found to be efficient on SARS-CoV-2, and reported to be efficient in Chinese COV-19 patients. We evaluate the role of hydroxychloroquine on respiratory viral loads. Patients and methods French Confirmed COVID-19 patients were included in a single arm protocol from early March to March 16th, to… 
Hydroxychloroquine and Azithromycin as a treatment of COVID-19: preliminary results of an open-label non-randomized clinical trial
TLDR
Hydxychloroquine is significantly associated with viral load reduction/disappearance in patients with COVID-19 and its effect is reinforced by Azithromycin.
Safety and efficacy of hydroxychloroquine for treatment of non-severe COVID-19 among adults in Uganda: a randomized open label phase II clinical trial
TLDR
The results show that HCQ 400 mg twice a day for the first day followed by 200 mg once daily for the next 4 days was safe but not associated with reduction in viral clearance or symptom resolution among adults with COVID-19 in Uganda.
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study
TLDR
There is urgency to evaluate the effectiveness of this potentially-life saving therapeutic strategy at a larger scale, both to treat and cure patients at an early stage before irreversible severe respiratory complications take hold and to decrease duration of carriage and avoid the spread of the disease.
Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance
TLDR
Among outpatients with early and mild COVID-19, the use of HCQ/AZT did not impact the time to viral clearance compared to placebo, and secondary outcomes were also not significantly improved with HCQ /AZT treatmentCompared to placebo.
Effect of hydroxychloroquine in viral clearance in nCOV-19 infected patient admitted in tertiary care centre, Ranchi, Jharkhand, India
TLDR
There is no significant difference found in attaining virus negative status with use of HCQS administration in COVID-19 patients of authors own local population in this study.
Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial
TLDR
In patients with mild Covid-19, no benefit was observed with HCQ beyond the usual care and the time to complete resolution of symptoms was shortened.
Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials
TLDR
Hydxychloroquine or chloroquine use did not have a significant effect on virological cure, the time of clinical recovery, and improvement in survival in COVID-19 patients, however, patients who used hydroxy chlorineoquine showed an increase in adverse effects.
Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)?
TLDR
A potential interest of the combination therapy using HCQ/azithromycin for the treatment of COVID-19 in in-hospital patients is suggested.
Hydroxychloroquine and Azithromycin Treatment of Hospitalized Patients Infected with SARS-CoV-2 in Senegal from March to October 2020
TLDR
It was found that the proportion of patient discharge at D15 was significantly higher for patients receiving HCQ plus AZM (OR: 1.63), and an improvement of clinical status at 15 days was found for patients exposed to HCQ + AZM combination.
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
TLDR
Administration of the HCQ+AZ combination before COVID-19 complications occur is safe and associated with very low fatality rate in patients, retrospectively report on 1061 SARS-CoV-2 positive tested patients.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 112 REFERENCES
Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial
TLDR
In patients with mild Covid-19, no benefit was observed with HCQ beyond the usual care and the time to complete resolution of symptoms was shortened.
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial.
TLDR
In patients hospitalized with COVID-19, hydroxychloroquine was not associated with reductions in 28-day mortality but was associated with an increased length of hospital stay and increased risk of progressing to invasive mechanical ventilation or death.
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
TLDR
Among patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality.
Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study
TLDR
Hydroxychloroquine treatment with an initial loading dose of 800mg improved patient survival when admitted in early stages of the disease and there was a non-statistically significant trend towards survival in all groups.
Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study
TLDR
Adding HCQ to standard care did not add significant benefit, did not decrease the need for ventilation, and did not reduce mortality rates in COVID-19 patients, according to univariate logistic regression analysis.
Azithromycin and Hydroxychloroquine Accelerate Recovery of Outpatients with Mild/Moderate COVID-19
TLDR
AZM and AZM+HCQ favourably impacted the course of the disease, although the dual therapy tended to be more effective in patients over 50 years, based on an analysis using the cox model.
Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19
TLDR
The role of hydroxychloroquine therapy alone and in combination with azithromycin in hospitalized patients positive for COVID-19 was evaluated, and the primary outcome was in-hospital mortality.
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
TLDR
In critically ill patients admitted for SARS-CoV-2-related pneumonia, no difference was found between hydroxychloroquine or lopinavir/ritonavir as compared to standard of care only on the proportion of patients who needed treatment escalation at day 28.
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis
TLDR
Results suggest that early diagnosis, early isolation and early treatment of COVID-19 patients, with at least 3 days of HCQ-AZ lead to a significantly better clinical outcome and a faster viral load reduction than other treatments.
Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France
TLDR
A large non-selected population of inpatients hospitalized for COVID-19 infection in 39 hospitals in France and robust methodological approaches found no evidence for efficacy of HCQ or HCQ combined with AZI on 28-day mortality, supporting the need to complete currently undergoing randomized clinical trials.
...
1
2
3
4
5
...